Ultragenyx Reaches Deal to Divest FDA Priority Review Voucher for $210 Million

Ultragenyx Pharmaceutical entered into a formal arrangement on October 7, 2026, to monetize an asset granted under federal pharmaceutical incentive rules.¹ Under the terms disclosed by the company, the Rare Pediatric Disease Priority Review Voucher was agreed to be sold for a total valuation of $210 million.¹ This financial agreement secures a substantial monetary inflow for the enterprise in exchange for surrendering the expedited review instrument.¹ The transaction was announced publicly by Ultragenyx on October 7, 2026, marking an agreement to transfer the specialized regulatory credit.¹

The entitlement to this specific voucher stemmed directly from the regulatory clearance granted to the product known as GENGLYCOS, which also carries the development designation DTX401.¹ Ultragenyx obtained the review instrument from the U.S. Food and Drug Administration following that agency's formal approval of the medication.¹ According to the company's descriptions, GENGLYCOS stands as the initial therapeutic option created specifically to correct the biological root cause behind glycogen storage disease type Ia.¹ By targeting the underlying genetic pathology rather than simply mitigating external symptoms, DTX401 fulfilled the criteria needed to obtain the underlying incentive.¹

The voucher originated through the Rare Pediatric Disease Priority Review Voucher Program maintained by the U.S. Food and Drug Administration.¹ This government framework was established specifically to foster the creation of biological remedies and pharmaceutical compounds aimed at uncommon conditions afflicting younger populations.¹ Drug developers qualify to earn an award when they secure regulatory authorization for eligible products that address designated rare pediatric illnesses.¹ The granting of the credential takes place at the exact moment the regulatory agency officially greenlights the application for the qualifying pediatric product.¹

Possessing one of these regulatory instruments allows the holder to secure priority review status on a subsequent marketing submission for an entirely different medicine.¹ This mechanism drastically shortens the duration of the evaluation timeline for that future product candidate before the agency.¹ Under the established provisions of the federal incentive structure, an awarded voucher can be lawfully transferred or divested to an external commercial party.¹ Because the voucher is uncoupled from the drug that generated it, Ultragenyx was permitted to sell the regulatory asset on the market.¹

Executive leadership at Ultragenyx highlighted the financial strategic importance of converting the regulatory asset into liquid funds.¹ Howard Horn, who acts as the company's chief financial officer as well as its executive vice president of corporate strategy, stated that the transaction delivers meaningful non-dilutive funding.¹ Horn explained that obtaining non-dilutive resources through the sale enables the company to fund its operations without distributing additional corporate equity.¹ The chief financial officer remarked that these newly generated resources will help advance the company along its planned trajectory toward achieving sustained profitability.¹ He further specified that the incoming capital will be directed into research efforts to create groundbreaking therapies for rare and ultra-rare medical conditions.¹

The monetization of regulatory incentives forms an established funding approach within Ultragenyx's long-term research pipeline.¹ Howard Horn noted that the clinical progression of GENGLYCOS itself was directly supported by financial resources derived from a past voucher transaction.¹ By reinvesting proceeds realized from earlier voucher sales, the biopharmaceutical developer succeeded in shepherding DTX401 through the development milestones needed to gain final approval.¹ This previous capital deployment created the exact regulatory milestone that yielded the $210 million voucher currently slated for divestment.¹

Ultragenyx categorizes its core business as a biopharmaceutical organization committed to originating treatments for severe, life-impairing genetic diseases classified as rare or ultra-rare.¹ Its overall corporate pipeline encompasses both commercialized drugs and clinical-stage investigational candidates aimed at illnesses displaying clear biological pathways alongside acute unmet patient needs.¹ The firm focuses its scientific efforts on medical conditions that typically lack any pre-existing approved treatments capable of rectifying the underlying biological disease state.¹ The pursuit of GENGLYCOS for glycogen storage disease type Ia directly mirrors this overarching focus on unresolved root-cause genetic pathologies.¹

Executing the $210 million agreement involved professional advisory representation on both financial and legal fronts.¹ Jefferies LLC was selected by Ultragenyx to act as the sole financial advisor handling the transaction.¹ Corporate legal counsel throughout the drafting and closing stages of the transaction is being provided by Gibson, Dunn and Crutcher LLP.¹ The completion of the voucher transfer remains subject to conventional closing mandates, specifically requiring the expiration of the statutory review timeline mandated by the Hart-Scott-Rodino Antitrust Improvements Act.¹

Ultragenyx explicitly cautioned that the projected schedule, the ultimate receipt of the cash funds, and the subsequent deployment of the capital constitute forward-looking considerations.¹ The firm warned stakeholders that should mandatory closing obligations remain unfulfilled, the execution of the sale could face significant postponements or collapse completely.¹ Broader corporate and operational uncertainties, including unpredictability in clinical trial execution and the drug approval environment, were cataloged as factors capable of impacting prospective business results.¹ Further comprehensive evaluations of these organizational risks were referenced in the company's Form 10-Q quarterly filing, which was officially submitted to the Securities and Exchange Commission on August 5, 2026.¹